| Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer (NCT06745219) | Peking University Cancer Hospital & Institute | 2025-01-01 |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM (NCT06352866) | Jack Khouri, MD | 2025-01-01 |
| Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy (NCT06746961) | The First Affiliated Hospital of Zhengzhou University | 2025-01-01 |
| PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study (NCT06666010) | Filament Health Corp. | 2025-01-01 |
| Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer (NCT07034326) | Kong Fanming | 2025-01-01 |
| Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients (NCT07576634) | Mansoura University | 2025-01-01 |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC (NCT07364305) | Eastern Hepatobiliary Surgery Hospital | 2025-01-01 |
| An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD (NCT06082817) | San Diego Sexual Medicine | 2025-01-01 |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases (NCT06774664) | Sinocelltech Ltd. | 2025-01-01 |
| A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment (NCT06677255) | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | 2025-01-01 |
| The Effect of Human Umbilical Cord Mesenchymal Stem Cells and Exosomes on the Healing of Postoperative Pain and Periapical Lesions in the Treatment of Apical Periodontitis: Randomized Controlled Clinical Study (NCT06764004) | TC Erciyes University | 2025-01-01 |
| Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins (NCT06595680) | Hospices Civils de Lyon | 2025-01-01 |
| Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer (NCT06766643) | Tianjin Medical University Cancer Institute and Hospital | 2025-01-01 |
| Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial (NCT06662253) | Alexandre Tran | 2025-01-01 |
| Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (NCT06441097) | Ruijin Hospital | 2024-12-31 |
| A Phase IIa Study in Primary IgA Nephropathy Patients (NCT07634744) | S-INFINITY Pharmaceuticals Co., Ltd | 2024-12-31 |
| Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (NCT06510010) | Sixth Affiliated Hospital, Sun Yat-sen University | 2024-12-31 |
| L-carnitine Supplementation in Rheumatoid Arthritis Patients (NCT06753565) | German University in Cairo | 2024-12-31 |
| Dynamic CtDNA-guided Targeted Therapy in DLBCL (NCT06748521) | Ruijin Hospital | 2024-12-31 |
| A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis (NCT06912165) | Zhejiang Wenda Pharma Technology LTD. | 2024-12-31 |
| Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC (NCT06752382) | Zhejiang Cancer Hospital | 2024-12-31 |
| CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) (NCT06750991) | Ruijin Hospital | 2024-12-31 |
| Evaluation of BTV100 in Subjects With Dry Eye Disease (NCT06543303) | BioTheraVision, Inc. | 2024-12-31 |
| CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors (NCT06720324) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-12-31 |
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (NCT06581419) | SUNHO（China）BioPharmaceutical CO., Ltd. | 2024-12-31 |
| A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06707883) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2024-12-31 |
| Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL (NCT07195799) | The First Affiliated Hospital with Nanjing Medical University | 2024-12-31 |
| Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA (NCT06739252) | Peking University | 2024-12-31 |
| XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC (NCT06742411) | West China Hospital | 2024-12-31 |
| Study of HRS-2189 Combined HRS-5041 in Prostate Cancer (NCT06738745) | Fudan University | 2024-12-31 |
| JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial (NCT06715982) | Shixiu Wu | 2024-12-31 |
| A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer (NCT06769919) | Xijing Hospital | 2024-12-31 |
| Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) (NCT06759181) | Xuzhou Medical University | 2024-12-31 |
| Evaluation Of Marginal Bone Height Changes And Biting Force In Screw Retained Implant Prostheses Using Reinforced Resin Vs Monolithic Zirconium (NCT07007572) | Cairo University | 2024-12-31 |
| Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer (NCT06764680) | Sun Yat-sen University | 2024-12-31 |
| A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies (NCT06668584) | M.D. Anderson Cancer Center | 2024-12-31 |
| An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation. (NCT06753721) | Nanfang Hospital, Southern Medical University | 2024-12-31 |
| Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) (NCT06687174) | Wuhan Createrna Science and Technology Co., Ltd | 2024-12-31 |
| HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies (NCT06649708) | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. | 2024-12-30 |
| Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06766578) | Shandong Provincial Hospital | 2024-12-30 |
| ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial (NCT06664879) | M.D. Anderson Cancer Center | 2024-12-30 |
| Effect of Honey For CIN II (NCT06219018) | Zuyderland Medisch Centrum | 2024-12-30 |
| A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination (NCT05911048) | WestVac Biopharma Co., Ltd. | 2024-12-30 |
| Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC (NCT06876844) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2024-12-30 |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures (NCT06798896) | Supernus Pharmaceuticals, Inc. | 2024-12-30 |
| An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus (NCT06730672) | Sun Yat-sen University | 2024-12-30 |
| Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study (NCT07245667) | Propedix, Inc. | 2024-12-30 |
| A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine (NCT06619509) | Boehringer Ingelheim | 2024-12-30 |
| TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT06598969) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2024-12-30 |
| Acute Agitation in Emergency Psychiatry (NCT06752616) | Lone Baandrup | 2024-12-30 |
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (NCT06664125) | Jemincare | 2024-12-30 |
| Rifaximin SSD in Dementia Trial (NCT06718686) | Jasmohan Bajaj | 2024-12-30 |
| A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) (NCT06756126) | Akeso | 2024-12-30 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection (NCT07183306) | Suzhou HepaThera Biotech Co., Ltd. | 2024-12-30 |
| Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant (NCT05982275) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2024-12-30 |
| Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease (NCT06765993) | Lunan Better Pharmaceutical Co., LTD. | 2024-12-30 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT07461181) | Ruijin Hospital | 2024-12-30 |
| A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) (NCT06749457) | AstraZeneca | 2024-12-30 |
| Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma (NCT06764251) | Liaoning Cancer Hospital & Institute | 2024-12-30 |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) (NCT06524830) | atai Therapeutics, Inc. | 2024-12-30 |
| Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors (NCT07415863) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2024-12-30 |
| Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC (NCT06752798) | Hunan Cancer Hospital | 2024-12-30 |
| Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma (NCT06757387) | Peking University Cancer Hospital & Institute | 2024-12-30 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy (NCT06263153) | Yuanquan Yang | 2024-12-30 |
| Liposomal Irinotecan and Apatinib in ES-SCLC (NCT06749691) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-12-28 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (NCT06390319) | St. Jude Children's Research Hospital | 2024-12-27 |
| Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma (NCT06516887) | The University of Texas Health Science Center at San Antonio | 2024-12-27 |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (NCT06078384) | UNICANCER | 2024-12-27 |
| Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma (NCT06446154) | Sun Yat-sen University | 2024-12-27 |
| A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma (NCT06650514) | Vall d'Hebron Institute of Oncology | 2024-12-27 |
| Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID (NCT06597396) | Beth Israel Deaconess Medical Center | 2024-12-27 |
| A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) (NCT06593522) | Amgen | 2024-12-26 |
| An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma (NCT06668792) | Biocad | 2024-12-26 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases (NCT06794008) | Peking University People's Hospital | 2024-12-26 |
| Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) (NCT06494150) | University of Oklahoma | 2024-12-26 |
| Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer (NCT06671262) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-12-26 |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial (NCT06432036) | Jonsson Comprehensive Cancer Center | 2024-12-26 |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder (NCT06785012) | Janssen Research & Development, LLC | 2024-12-26 |
| BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia (NCT06746519) | Chen Suning | 2024-12-25 |
| Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer (NCT06748508) | Fudan University | 2024-12-25 |
| A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies (NCT06971523) | CytosinLab Therapeutics Co., Ltd. | 2024-12-25 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas (NCT06716658) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-25 |
| The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. (NCT06764329) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2024-12-25 |
| Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy (NCT06596018) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-12-25 |
| A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts. (NCT06718192) | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 2024-12-25 |
| Pembrolizumab in Locally Advanced Sinonasal Carcinoma (NCT05925491) | Istituti Clinici Scientifici Maugeri SpA | 2024-12-24 |
| First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy (NCT06667167) | Nir Peled | 2024-12-24 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma (NCT06692452) | Eric Jacobsen, MD | 2024-12-24 |
| A Study of Enasidenib in People With T-Cell Lymphoma (NCT06756308) | Memorial Sloan Kettering Cancer Center | 2024-12-24 |
| A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head (NCT07471880) | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 2024-12-24 |
| A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06423885) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-12-24 |
| Remotely Observed Methadone Evaluation II (NCT06338280) | Sonara Health | 2024-12-24 |
| A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia (NCT06752668) | Centessa Pharmaceuticals (UK) Limited | 2024-12-23 |
| Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy (NCT06660355) | H. Lee Moffitt Cancer Center and Research Institute | 2024-12-23 |
| Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma (NCT06771544) | University of California, Irvine | 2024-12-23 |
| Trop2-targeted immunoPET Imaging of Solid Tumors (NCT06851663) | RenJi Hospital | 2024-12-23 |
| Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial (NCT07364747) | Siriraj Hospital | 2024-12-23 |
| mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer (NCT06761027) | Fujian Provincial Hospital | 2024-12-23 |
| Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome (NCT06618495) | Xiyuan Hospital of China Academy of Chinese Medical Sciences | 2024-12-23 |
| Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors (NCT06735144) | Jiangsu HengRui Medicine Co., Ltd. | 2024-12-23 |